Imprimis Pharmaceuticals, Inc. (IMMY)
-NasdaqCM 8.73 
0.28(3.11%) May 17, 4:00PM EDT
| Prev Close: | 9.01 |
|---|
| Open: | 9.01 |
|---|
| Bid: | N/A |
|---|
| Ask: | 9.00 x 6200 |
|---|
| 1y Target Est: | 2.00 |
|---|
| Beta: | -0.49 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 8.73 - 9.10 |
|---|
| 52wk Range: | 2.55 - 30.00 |
|---|
| Volume: | 3,561 |
|---|
| Avg Vol (3m): | 29,710 |
|---|
| Market Cap: | 77.59M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.92 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage decreasesAP(Fri, May 17)
- IMPRIMIS PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Tue, May 14)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Imprimis Rising: Unique Pathway Requires Fewer and Smaller Clinical TrialsMarketwired(Wed, May 8)
- Imprimis Pharmaceuticals, Inc. Concludes Type C Meeting at the FDAPR Newswire(Thu, Apr 18)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Fri, Apr 12)
- 2 Biotech Stocks Under $10 to Watchat TheStreet(Thu, Apr 11)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Mar 18)
- Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment OptionPR Newswire(Wed, Mar 13)
- Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical ProductsPR Newswire(Mon, Mar 4)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements aEDGAR Online(Thu, Feb 21)
- Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAIDPR Newswire(Tue, Feb 19)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of EEDGAR Online(Fri, Feb 8)
- Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common StockPR Newswire(Thu, Feb 7)
- IMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, Dec 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 32,032.35 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-10)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Imprimis Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focusing on the commercial development of compounded drug formulations. The company, through an exclusive strategic relationship with Professional Compounding Centers of...
View More